CBX Therapeutics

About CBX Therapeutics

CBX Therapeutics is a science-first biotech company developing innovative, cannabinoid-based solutions for neurological and neurodegenerative disorders. Our approach is grounded in translational strategy, regulatory insight, and real-world clinical relevance, ensuring that every product we develop delivers clear therapeutic value and follows a defined, feasible path to market. We operate at the intersection of innovation, disciplined execution, and strategic focus. From first concept to clinical readiness, CBX applies a rigorous development model based on targeted indication selection, biomarker-informed product design, and a lean, milestone-driven execution framework. With active programs addressing neurological conditions primarily Parkinson's disease, we are building a differentiated portfolio supported by robust scientific rationale and early clinical momentum. CBX has developed a platform for next-generation cannabinoid formulations and applies it across discovery, development, and commercialization of proprietary products combining pharmacological precision with patient-centered outcomes. We welcome collaboration with clinical sites, distribution partners, and wellness brands who share our commitment to scientific integrity and real-world impact. With R&D operations based in Israel, and a business hub in California, CBX brings together global scientific expertise, regulatory strength, and commercial agility. Our mission is clear: to turn bold therapeutic concepts into trusted, effective products that backed by science, built for patients, and ready for the real world.

View contact profiles from CBX Therapeutics